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Background: Impaired BK channel function in diabetic vessels is associated with decreased BK channel 1 subunit (BK-1)
expression.
Results: Muscle RING finger protein 1 (MuRF1) physically interacts with BK-1 and accelerates BK-1 proteolysis.
Conclusion: Increased MuRF1 expression is a novel mechanism underlying diabetic BK channelopathy and vasculopathy.
Significance: MuRF1 is a potential therapeutic target of BK channel dysfunction and vascular complications in diabetes.
The large conductance Ca2-activated K (BK) channel,
expressed abundantly in vascular smooth muscle cells (SMCs),
is a key determinant of vascular tone. BK channel activity is
tightly regulated by its accessory 1 subunit (BK-1). However,
BK channel function is impaired in diabetic vessels by increased
ubiquitin/proteasome-dependent BK-1 protein degradation.
Muscle RING finger protein 1 (MuRF1), a muscle-specific ubiq-
uitin ligase, is implicated in many cardiac and skeletal muscle
diseases. However, the role of MuRF1 in the regulation of vas-
cular BK channel and coronary function has not been examined.
In this study, we hypothesized that MuRF1 participated in
BK-1 proteolysis, leading to the down-regulation of BK chan-
nel activation and impaired coronary function in diabetes. Com-
bining patch clamp and molecular biological approaches, we
found that MuRF1 expression was enhanced, accompanied by
reduced BK-1 expression, in high glucose-cultured human
coronary SMCs and in diabetic vessels. Knockdown of MuRF1
by siRNA in cultured human SMCs attenuated BK-1 ubiquiti-
nation and increased BK-1 expression, whereas adenoviral
expression of MuRF1 in mouse coronary arteries reduced
BK-1 expression and diminished BK channel-mediated vaso-
dilation. Physical interaction between the N terminus of BK-1
and the coiled-coil domain of MuRF1 was demonstrated by pull-
down assay. Moreover, MuRF1 expression was regulated by
NF-B. Most importantly, pharmacological inhibition of pro-
teasome and NF-B activities preserved BK-1 expression and
BK-channel-mediated coronary vasodilation in diabetic mice.
Hence, our results provide the first evidence that the up-regula-
tion of NF-B-dependent MuRF1 expression is a novel mecha-
nism that leads to BK channelopathy and vasculopathy in
diabetes.
Diabetes mellitus has become a global epidemic. In the
United States, 25.8 million people have diabetes, and another 79
million Americans are prediabetic. These figures will more than
double by 2030. Diabetes is an independent risk factor of vas-
cular pathology and a leading cause of cardiovascular morbidity
and mortality (1, 2). Major causes of vascular dysfunction in
diabetes involve both endothelium-dependent and endotheli-
um-independent mechanisms. There is a large body of evidence
showing the abnormality of vascular smooth muscle function in
diabetes. However, the underlying molecular mechanisms
remain unclear (3–9).
The large conductance Ca2-activated K (BK)3 channels,
densely populated in vascular smooth muscle cells (SMCs), play
a negative feedback role in the regulation of vascular tone. BK
channels are activated by the increase of intracellular free Ca2
concentrations ([Ca2]i) to generate spontaneous transient
outward currents, which hyperpolarizes the membrane poten-
tial of vascular SMCs, inactivates voltage-dependent Ca2
channels, and leads to vascular relaxation (8, 10 –14). Func-
tional vascular BK channels are octameric complexes with four
BK- and four BK-1 subunits. BK-1, encoded by the
KCNMB1 gene, is a key determinant of BK channel electro-
physiology, enhancing the BK- sensitivity to Ca2 and voltage
and allowing channel activation in the physiological ranges of
[Ca2]i and membrane potentials (15–18). Regulation of BK
channel activity by many biological mediators, such as polyun-
saturated fatty acids, thromboxane A2, and steroid hormones,
are mediated through BK-1 stimulation, demonstrating the
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physiological importance of BK-1 (19 –22). The clinical rele-
vance of BK-1 is underscored by the findings that down-reg-
ulation of BK-1 function contributes to hypertension and
renal disease but that a gain-of-function mutation of BK-1 is
associated with a low prevalence of diastolic hypertension in
humans (23–25). However, vascular BK channel function is
impaired in both type 1 and type 2 diabetes mellitus and is an
important ionic mechanism leading to diabetic vascular dys-
function. Current experimental evidence indicates that BK
channel malfunction in diabetic vessels is associated with a sig-
nificant down-regulation of BK-1 protein expression, result-
ing in Ca2 sparks/spontaneous transient outward current
uncoupling and loss of Ca2-mediated channel activation even
though the Ca2 spark amplitude and [Ca2]i were increased in
vascular SMCs of diabetes (8, 26 –30). We have reported previ-
ously that ex vivo expression of the KCNMB1 gene in diabetic
mouse coronary arteries rescued BK channel function and pre-
served normal coronary reactivity, suggesting that BK-1 is an
important molecular target for the treatment of diabetic vascu-
lar diseases (31). However, the molecular mechanisms that pro-
duce BK-1 down-regulation have not been thoroughly
delineated.
Protein homeostasis with a balanced regulation between syn-
theses and degradation is essential for normal cellular function.
The ubiquitin proteasome system (UPS) is a major pathway of
proteolysis, accounting for 80 –90% of intracellular protein
degradation in mammalian cells (32). This process is facilitated
by three distinct enzymatic steps that involve an ubiquitin-ac-
tivating enzyme (E1), an ubiquitin-conjugating enzyme (E2),
and an ubiquitin ligase (E3). E1 activates ubiquitin, E2 accepts
the transfer of activated ubiquitin, and E3 selects proteins for
ubiquitination. Finally, the polyubiquitinated target proteins
are degraded to short peptides in the 26 S proteasome (32). Of
these, the E3 reaction is critical for the system because it recog-
nizes the targeted substrates for ubiquitination and confers
specificity of protein turnover. There are 617 E3 ligases func-
tionally annotated in the human genome (33). The muscle
RING finger (MuRF) protein family, comprised of three mem-
bers (MuRF1, MuRF2, and MuRF3), is a group of muscle-spe-
cific E3s. All three isoforms are specifically expressed in cardiac
and skeletal muscles and contain four important structures: a
RING finger domain, a MuRF family conserved region, a
“B-box” domain, and multiple coiled-coil domains (34).
MuRF1, in particular, has been implicated in many heart dis-
eases, including myocardial hypertrophy, myocardial atrophy,
ischemia, heart failure, myocarditis, and familial cardiomyopa-
thy (35, 36). Human genetic and functional studies have
revealed the clinical significance of MuRF1, which confirmed
that MuRF1 mutations cause hypertrophic cardiomyopathy in
patients (37). However, the role of MuRF1 in vascular diseases
is unclear.
The NF-B complex is composed of the p65 (RelA), RelB,
c-Rel, and p105/p50 (NF-B1) or p100/p52 (NF-B2) subunits.
In unstimulated cells, p65 is bound to an inhibitory subunit
(IB) that keeps it sequestered in an inactive state in the cyto-
plasm. Phosphorylation of IB by IB kinase (IKK) leads to its
dissociation from p65, which facilitates p65/p50 or p65/p52
dimeric complex nuclear translocation and promotes its tran-
scriptional activity (38). In addition, the unbound phospho-IB
is degraded through the UPS. MuRF1 is one of the target genes
regulated by NF-B (39). In this study, we report that the
MuRF1 physically interacted with BK-1 and down-regulated
BK-1 expression through MuRF1-facilitated, UPS-dependent
BK-1 proteolysis. MuRF1 expression was controlled by
NF-B, which is up-regulated in diabetic vessels, leading to
acceleration of BK-1 proteolysis. Most importantly, knock-
down of MuRF1 or inhibition of proteasome and NF-B activ-
ities significantly enhanced BK-1 expression, restored vascu-
lar BK channel activity, and preserved coronary function in
diabetes. Our results identified a fundamental mechanism that
underlies diabetic BK channelopathy and vasculopathy. There-
fore, MuRF1 is a potential novel target for the treatment of
vascular complications in diabetes.
EXPERIMENTAL PROCEDURES
STZ-induced Diabetic Mice—Male mice (strain C57BL/CJ) 4
weeks of age were purchased from The Jackson Laboratory (Bar
Harbor, ME). Animals were made diabetic by an injection of
STZ (100 mg/kg body weight, intraperitoneally). Animals with
blood glucose 300 mg/dl were considered diabetic and were
used for experiments 8 weeks after developing hyperglycemia.
All protocols were approved by the Institutional Animal Care
and Use Committee of the Mayo Clinic, Rochester, MN.
Coronary Artery SMC Isolation—Mouse coronary SMCs
were isolated enzymatically as described previously (40). In
brief, the coronary arteries were carefully dissected in ice-cold
dissociation buffer (145 mM NaCl, 4.0 mM KCl, 0.05 mM CaCl2,
1.0 mM MgCl2, 10 mM HEPES, and 10 mM glucose (pH 7.2)).
The vessels were placed in dissociation buffer containing 0.1%
w/v BSA and incubated in a shaking water bath at 37 °C for 3
min. The vessels were incubated with fresh 0.1% w/v BSA dis-
sociation buffer containing 1.5 mg/ml papain and 1.0 mg/ml
dithiothreitol in a shaking water bath at 37 °C for another 3 min.
This was followed by digestion in fresh 0.1% w/v BSA dissocia-
tion buffer containing 1.0 mg/ml collagenase and 1.0 mg/ml of
trypsin inhibitor at 37 °C for 3 min. The vessels were stored in 2
ml of dissociation buffer triturated gently with a fire-polished
glass pipette until the cells were completely dissociated.
BK Channel Current Recordings—Single channel currents
were elicited at 60 mV from inside-out excised membrane
patches using an Axopatch 200B (Axon Instruments, Inc.) (27,
31, 41). The output signals were filtered with an 8-pole Bessel
filter (902 LPF, Frequency Devices, Inc.) at 5 kHz and digitized
at 50 kHz. Patch pipettes had a typical tip resistance of 5–10 M
when filled with the pipette solution, which contained 140 mM
KCl, 1 mM CaCl2, 1 mM MgCl2, 1 mM EGTA, and 10 mM HEPES
(pH 7.4) with KOH. The bath solution contained 140 mM KCl, 1
mM MgCl2, 1 mM EGTA, 0.465 mM CaCl2 (0.2 M free Ca2,
calculated using Chelator software), and 10 mM HEPES (pH
7.35) with KOH. The inside-out single BK currents were deter-
mined by its unitary current amplitude (i) and sensitivity to free
Ca2 concentrations, as described previously (41). Normalized
channel open probability (NPo) was determined by the follow-
ing equation (42):
NPo(tnn)/T (Eq. 1)
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where t represents the open time of a channel obtained at a
distinct level (n), and T is the total recording time.
The effects of dehydrosoyasaponin-1 (DHS-1, a BK-1-spe-
cific activator) on BK channel open probability (Po) were mea-
sured in the same membrane patch before and after drug appli-
cation to the cytoplasmic surface. After the DHS-1 experiments
were completed, the total number of channels in each mem-
brane preparation was determined by exposure to 10 M Ca2
that activates all channels in the patch and produces the maxi-
mal BK channel Po in coronary SMCs (41). All patch clamp
experiments were performed at room temperature (22–24 °C).
Data analysis was performed using Clampfit 10.2 software
(Axon Instruments, Inc.).
Cell Culture, Subcloning, Site-directed Mutagenesis, cDNA
Transfection, Adenoviral Gene Transduction, and mRNA
Knockdown—Mouse MuRF1 WT with a Myc tag in the N
terminus (Myc-MuRF1 WT, amino acids 1351) (accession
no. DQ229108), the RING finger deletion mutant (Myc-
MuRF1R, amino acids 79351), the family conserved region
deletion mutant (Myc-MuRF1FMC, amino acids 100351),
and the B-box deletion mutant (Myc-MuRF1B, amino acids
160351) cDNAs in pCMV Tag3B as well as an adenovirus
carrying MuRF1 (Ad-MuRF1) and the GFP gene (Ad-GFP)
were prepared by Dr. Monte S. Willis (University of North Car-
olina at Chapel Hill). Myc-MuRF1B with deletion of the last
10 C-terminal amino acid residues (Myc-MuRF1BC, amino
acids 160340) was created by introducing a stop codon using
the QuikChange site-directed mutagenesis kit (Stratagene,
Inc.) (43).
Human BK-1 WT cDNA (amino acids 1191) (accession
no. MN_004137.3) was subcloned into pIRES2-EGFP with two
FLAG tags in the N-terminal of BK-1 (28). Three FLAG-
BK-1 truncation mutants, the N-terminal mutant (amino
acids 139), the transmembrane domain mutant (amino acids
15179), and the C-terminal mutant (amino acids 155191)
were also constructed. The orientations of the constructs and
the correctness of the mutation were verified by DNA sequenc-
ing (DNA Facility Core of the Mayo Clinic, Rochester, MN).
MuRF1 siRNA and control siRNA were obtained from Santa
Cruz Biotechnology, Inc. HA-tagged human ubiquitin (HA-
ubiquitin) in pcDNA3 was obtained from Addgene, Inc. cDNAs
and siRNA transfection were conducted using a Lipofectamine
2000 transfection kit (Invitrogen). The aortas and coronary
arteries of mice were transduced with Ad-MuRF1 and Ad-GFP
at 1  1011 particles/ml for 12 h (28, 31).
HEK293 cells were cultured in DMEM. Primary human cor-
onary SMCs were purchased from Lonza Walkersville, Inc. and
were cultured with Clonetics SmBM (Lonza Walkersville, Inc.)
containing 5 mM glucose (normal glucose, NG) or 22 mM glu-
cose (high glucose, HG). All experiments were performed using
cells between passages 4 and 5.
Videomicroscopy—Vasoreactivity was measured as described
previously (31, 44). Isolated mouse coronary arteries (1–2 mm
in length and 80 –130 m in diameter) were mounted in a vessel
chamber filled with Krebs solution containing 118.3 mM NaCl,
4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 1.2 mM KH2PO4, 25
mM NaHCO3, and 11.1 mM glucose (pH 7.4) and were secured
between two borosilicate glass micropipettes with a 10-O oph-
thalmic suture. The lumen of each vessel was filled with Krebs
solution through the micropipettes and maintained at a con-
stant pressure (no flow) of 60 mm Hg, followed by equilibration
for 60 min in oxygenated (20% O2  5% CO2 balanced with N2,
37 °C) Krebs solution. The vessels were deemed unacceptable
for experiments if they demonstrated leaks or failed to produce
more than a 50% constriction to graded doses of endothelin-1.
The endothelium was denuded by slowly perfusing 3–5 ml of
air through the lumen of unpressurized vessels. The effective-
ness of endothelium denudation was verified by demonstrating
that the vessel failed to dilate to 1 M acetylcholine, constricted
normally to ET-1, and dilated normally to 100 M sodium nitro-
prusside. Concentration-response relationships of NS-1619
(10	9-10	5 M) on vasodilatation were measured, and compari-
sons were made in mouse coronary arteries 12 h after transduc-
tion with Ad-GFP, Ad-MuRF1, or Ad-MuRF1 in the presence
of 10 M MG132. At the end of each experiment, vessels were
maximally dilated with a Ca2-free solution, and the percent-
age of dilatation in response to NS-1619 was normalized to the
maximal diameter.
Coimmunoprecipitation (Co-IP) and Western Blot Analysis—
Co-IP was performed as described previously (40). Transfected
HEK293 cells were washed with PBS three times. The aortas or
collected cells were incubated with 200 l of radioimmune pre-
cipitation assay buffer (50 mM Tris, 150 mM NaCl, 1 mM NaF2, 1
mM EDTA, 1 mM EGTA, 1 mM NaVO4, and 1% Triton X-100
(pH 7.5)) and 1 l of protease inhibitor on ice for 30 min,
homogenized, and then centrifuged at 8000 rpm at 4 °C for 10
min. The supernatant (about 200 g in 200 l) was incubated
with anti-HA (Sigma-Aldrich) or anti-FLAG (Cell Signaling
Technology, Inc.) antibodies at a final concentration of 4 g/ml
for each at 4 °C overnight. The samples were then incubated
with 20 l protein G Plus-agarose (Santa Cruz Biotechnology,
Inc.) at 4 °C for 2 h with rotation. After centrifugation at 1000
rpm for 7 min and washing twice with radioimmune precipita-
tion assay/protease inhibitor buffer, the immunoprecipitates
were collected and eluted from agarose with 30 l of SDS-
PAGE loading buffer/tube.
Blots were probed against anti-BK- (1:50, University of Cal-
ifornia at Davis), anti-BK-1 (1:200, customer-made) (28, 31),
anti-MuRF1 (1:200, ECM Biosciences, LLC), anti-NF-B/p105
(Cell Signaling Technology Inc.), anti-p65 (Cell Signaling Tech-
nology Inc.), anti-IB (1:200, Abcam), anti-FLAG (1:2000,
Sigma-Aldrich), anti-HA (1:2000, Sigma-Aldrich), anti-Myc
(1:2000, Sigma-Aldrich), and anti-ubiquitin (1:100, Santa Cruz
Biotechnology, Inc.) antibodies. Protein expression was
expressed as relative abundance normalized to -actin or
GAPDH (1:2000, Sigma-Aldrich). Optical density of the bands
was analyzed using Scion Image software (Scion).
Size Exclusion Chromatography—Chromatographic separa-
tion of FLAG-BK-1(1–39) and Myc-MuRF1 mutant proteins
was performed by the Mayo Clinic Proteomics Center (Roch-
ester, MN) using a Superdex 75 10/300 column (GE Health-
care). Samples (350 l) were equilibrated in radioimmune pre-
cipitation assay buffer and run through the size exclusion
column with a flow rate of 0.4 ml/min. 48 fractions (0.4 ml each)
were collected. Standard proteins with known molecular
weights (Gel Filtration Standards, Bio-Rad Laboratories) in
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phosphate-buffered saline were run under the same conditions.
The presence of FLAG-BK-1 and Myc-MuRF1 proteins in
each fraction (30 l) were measured using Western blot ana-
lyses, and the band intensities were plotted against standard pro-
tein peaks (bovine thyroglobulin, 670 kDa; bovine IgG, 158 kDa;
chicken ovalbumin, 44 kDa; horse myoglobin, 17 kDa, and Vita-
min B12, 1350 Da) to estimate the size of proteins.
Chemicals—2-[(Aminocarbonyl)amino]-5-(4-fluorophenyl)-
3-thiophenecarboxamide (TPCA-1) was purchased from Toc-
ris Bioscience Co. Unless mentioned otherwise, all other chem-
icals were obtained from Sigma-Aldrich.
Statistical Analysis—All data are expressed as mean 
 S.E.
Student’s t test was employed to compare data between two
groups, and a paired t test was used to compare data before and
after treatment. One-way analysis of variance followed by the
Tukey test analysis was used to compare multiple groups using
SigmaStat software (Jandel Scientific Software, Inc.). A statisti-
cally significant difference was defined as p  0.05.
RESULTS
Type 1 Diabetic Mice—Male mice at 4 weeks of age received
a single dose of STZ (100 mg/kg body weight, intraperitone-
ally), whereas controls received saline injections. Eight weeks
after injection, the average body weights and blood glucose lev-
els were 28.05 
 0.82 g (n  30) and 181.43 
 5.32 mg/dl (n 
30) in control mice and 23.61 
 0.88 g (n  30, p  0.05 versus
control) and 466.22 
 18.05 mg/dl (n  30, p  0.05 versus
control) in diabetic mice, respectively. Hence, STZ-induced
diabetic mice had a 15.8% decrease in body weight and a 157.0%
increase in blood glucose level.
Diminished BK-1-mediated BK Channel Activation and
Reduced BK-1 Protein Expression in Vascular SMCs from
Diabetic Mice and in Human Coronary SMCs Cultured with
HG—Inside-out single BK channel currents were recorded
from the freshly isolated coronary SMCs of control and diabetic
mice. BK channel NPo at baseline was 0.19 
 0.07 (n  11) in
control SMCs and was reduced significantly in diabetic SMCs
(0.01 
 0.004, n  11, p  0.05 versus control). The BK-1-
mediated channel activation was determined by cytoplasmic
exposure to 0.1 M DHS-1 (a BK-1-specific activator), which
resulted in a 5.5-fold increase in NPo (1.10 
 0.30, n  11, p 
0.05 versus baseline) in control mice. In diabetic coronary
SMCs, there was a small but significant increase in response to
DHS-1 stimulation (0.05 
 0.01, n  11, p  0.05 versus dia-
betic baseline) (Fig. 1A). Fig. 1B (left panel) represents a full-
lane Western blot analysis of anti-ubiquitin antibody against
the lysates of control and diabetic mouse aortas and shows an
increase of total ubiquitinated proteins in diabetic aortas. To
determine and compare the level of ubiquitinated BK-1 pro-
tein in control and diabetic vessels, we performed a pulldown
assay of control and diabetic mouse aortas with anti-BK-1
antibodies, followed by Western blotting against anti-ubiquitin
antibody. There was a 1.56 
 0.28-fold increase in BK-1 ubiq-
uitination in diabetic aortas (n  4, p  0.05 versus control)
(Fig. 1B, right panel). Importantly, BK-1 expression was
down-regulated by 0.51 
 0.13-fold (n  3, p  0.05, versus
control) in diabetic mouse aortas, accompanied by a 2.83 

0.16-fold increase in MuRF1 expression (n  3, p  0.05, versus
control) (Fig. 1C). Similar results were observed in human cor-
onary SMCs after a 2-week culture with HG, where BK-1
expression was 0.60 
 0.05-fold lower and MuRF1 expression
was 1.84 
 0.21-fold higher than cells cultured with NG (n  3,
p  0.05 in both) (Fig. 1D). Note that the changes in protein
expression profiles in HG culture conditions were not due to
osmolality of culture mediums under our experimental condi-
tions because human coronary SMCs cultured with 5 mM glu-
cose plus 17 mM mannitol did not alter the protein levels of
BK-1 and MuRF1 compared with those cultured with NG
alone (data not shown). In addition, we have shown that the
BK-1 mRNA level was not reduced in STZ-induced diabetic
vessels or in HG-cultured human coronary SMCs (28). Hence,
the impaired BK channel function in diabetes is most likely due
to accelerated BK-1 degradation from increased MuRF1
expression.
Regulation of BK-1 Expression and Vascular BK Channel
Function by MuRF1—To confirm the role of MuRF1 in the
regulation of BK-1 expression, we examined the level of
BK-1 protein expression in HG-cultured human coronary
SMCs transfected with MuRF1 siRNA or with control siRNA.
48 h after transfection with 0.1 M MuRF1 siRNA, MuRF1
expression was down-regulated by 76.1 
 5.9% (n  3, p  0.05
versus control siRNA), whereas that of BK-1 was augmented
by 86.1 
 14.7% (n  3, p  0.05 versus control siRNA) (Fig.
2A). Knockdown of MuRF1 preserved BK-1 protein expres-
sion to a level similar as that in NG-cultured cells.
Fig. 2B shows HEK293 cells stably expressing FLAG-BK-1
WT 48 h after transient expression with Myc-MuRF1 WT or
Myc-MuRF1R (an inactive mutant with the RING structure
deletion). There was a 2.58 
 0.14-fold increase in BK-1
expression (n  3, p  0.05) in the cells expressing Myc-
MuRF1R compared with the cells expressing Myc-MuRF1
WT. However, coexpression of Myc-MuRF1 WT did not
change the protein level of BK- stably expressed in HEK293
cells. Moreover, cotransfection of HA-ubiquitin with Myc-
MuRF1 WT produced a 5-fold increase in ubiquitinated BK-1
protein in the immunoprecipitates against anti-HA antibody or
anti-FLAG antibody compared with those in the cells with HA-
ubiquitin and Myc-MuRF1R cotransfection (Fig. 2C).
The role of MuRF1 on the regulation of vascular BK channel
activity and coronary vasoreactivity was further demonstrated
by adenoviral-mediated overexpression of MuRF1 (Ad-
MuRF1) in control mouse arteries. As shown in Fig. 3A, there
was a 177.2 
 11.5% (n  3) increase of MuRF1 expression and
a 66.8 
 15.6% decrease of BK-1 expression in mouse aortas
12 h after transduction with Ad-MuRF1 compared with control
transduction with adenovirus carrying the GFP gene (Ad-GFP)
(Fig. 3A). Patch clamp studies confirmed that BK channel acti-
vation by 0.1 M DHS-1 was diminished in mouse coronary
SMCs 12 h after transduction with Ad-MuRF1, which was
accompanied by impaired coronary vasodilation in response to
NS1619 (a BK channel activator). The DHS-1-mediated BK
channel activation and the NS1619-induced (10	9-10	5 M)
vasodilation were intact in coronary arteries with Ad-GFP
transduction (Fig. 3, B and C). Moreover, the inhibitory effect of
Ad-MuRF1 on coronary vasoreactivity was abrogated by a 12-h
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treatment with 10 M MG132 (a proteasomal inhibitor) (Fig.
3C). Our results confirmed that MuRF1 reduced BK-1-medi-
ated channel activation and impaired coronary vasodilation
through MuRF1-dependent BK-1 protein ubiquitination and
protein turnover.
Functional Regions of BK-1 and MuRF1 Protein Complex
Formation—To gain further understanding on interaction
between BK-1 and MuRF1, we constructed a series of FLAG-
BK-1 truncation mutants, as shown in Fig. 4A. We coex-
pressed Myc-MuRF1 WT with individual FLAG-BK-1 trun-
cation mutants in HEK293 cells. The immunoprecipitates
pulled down by anti-Myc antibody from the cell lysates were
blotted against anti-FLAG antibody. As shown in Fig. 4A, the
co-IP with MuRF1 was detected only when the N-terminal
segment of BK-1(1–39) was present. Similarly, the domains in
MuRF1 for BK-1 interaction were determined by coexpres-
sion of FLAG-BK-1 WT with individual Myc-MuRF1 mu-
tants: Myc-MuRF1R, Myc-MuRF1MFC, Myc-MuRF1B,
and Myc-MuRF1BC (Fig. 4B). When the immunoprecipi-
tates of anti-FLAG antibody were blotted against anti-Myc
antibody, the co-IP with BK-1 was found in MuRF1 WT,
MuRF1B, and MuRF1BC mutants, indicating that the
FIGURE 1. Impaired BK-1-mediated channel activation, reduced BK-1 expression, and increased MuRF1 expression in diabetic vessels and in
HG-cultured human coronary SMCs. A, inside-out single-channel BK currents were elicited at 60 mV in freshly isolated coronary SMCs from control and
diabetic mice before and after exposure to DHS-1 (0.1 M). DHS-1 robustly increased BK channel NPo in control SMCs, but its effects were diminished in diabetic
SMCs. Dashed lines represent the channel closed state (c). B, left panel, the cell lysates of control and diabetic mouse aortas were blotted against anti-ubiquitin
antibody. Right panel, the immunoprecipitates (IPs) of anti-BK-1 antibodies were blotted against anti-ubiquitin (Ub) antibody, showing a significant increase
of ubiquitinated BK-1 protein in diabetic mice. Ctrl, control. C and D, a marked reduction of BK-1 expression in the aortas of diabetic mice compared with
those of control mice and in human coronary SMCs after a 2-week culture with 22 mM glucose (HG) compared with that with 5 mM glucose (NG) culture. Group
data with statistical analysis are shown in the bar graphs.
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coiled-coil region of MuRF1 is essential for the interaction with
BK-1 (Fig. 4B). Interestingly, BK-1 did not coimmunopre-
cipitate with MuRF1R and MuRF1MFC where the coiled-
coil region is present, suggesting that the MuRF1-BK-1 inter-
action is complex and may be influenced by additional factors.
To confirm that the protein-protein interaction was not due
to nonspecific protein aggregation, we further performed size
exclusion chromatography separations of FLAG-BK-1(1–39)
and Myc-MuRF1BC mutants. A 48-h after transfection with
a plasmid carrying FLAG-BK-1(1–39) or Myc-MuRF1BC
(160 –340) in HEK293 cells, respectively, the cell lysates were
separated by a size exclusion column, and 48 fractions (0.4 ml
each) were collected. Fig. 5A shows the protein expression of
FLAG-BK-1(1–39) and Myc-MuRF1BC in the fractions
of size exclusion chromatography. FLAG-BK-1(1–39) was
detected only in fractions 2326 with a molecular size about 17
kDa (Fig. 5A, top panel). The Myc-MuRF1BC mutant was
present in a fraction of 2325, with a molecular size about 27
kDa (Fig. 5A, bottom panel). The relative density of protein
expression plotted against equivalent fractions is illustrated in
Fig. 5B. Five protein standards with different molecular weights
were separated under the same running conditions (green line).
The distribution of FLAG-BK-1(1–39) (black line) was coe-
luted with the molecular size standard of horse myoglobin of 17
kDa. There was a slight left shift in Myc-MuRF1BC density
distribution between the molecular size standard of horse myo-
globin and chicken ovalbumin (44 kDa). An immunofluorescence
experiment confirmed that FLAG-BK-1(1–39) expressed on the
membrane of HEK293 cells (data not shown). Taken together,
FIGURE 2. Regulation of BK-1 expression by MuRF1. A, after a 2-week
culture in NG or HG, BK-1 protein expression in human coronary SMCs was
determined under the following conditions: NG culture alone, HG culture
after a 48-h transfection with control siRNA (0.1 M), and HG culture after
a 48-h transfection with MuRF1 siRNA (0.1 M). MuRF1 siRNA suppressed
MuRF1 expression under HG culture conditions to that of NG culture con-
ditions. Ctrl, control. B, FLAG-BK-1 or FLAG-BK- stably expressed in
HEK293 cells 48 h after cotransfection with Myc-MuRF1 WT cDNA or Myc-
MuRF1R mutant cDNA. The BK-1 protein level was halved in cells with
MuRF1 WT transfection, but BK- expression remained unchanged. N.S.,
not significant. C and D, coimmunoprecipitation experiment shows atten-
uated BK-1 protein ubiquitination in the pulldown complexes with anti-
HA-ubiquitin (anti-HA-Ub) antibodies or with anti-FLAG antibodies in
HEK293 cells after a 24-h transfection with MuRF1R compared with those
with MuRF1 WT. Group data with statistical analysis are shown in the bar
graphs.
FIGURE 3. Reduced BK-1 expression and BK-1-mediated channel acti-
vation in vascular SMCs by MuRF1 expression. A, fluorescence microscopy
images illustrate GPF expression in endothelially denudated mouse coronary
artery 12 h after transduction with Ad-GFP but not in a negative control
artery. Immunoblot analyses show increased MuRF1 and decreased BK-1
expression in the aortas of control (Ctrl) mice after a 12-h transduction with
Ad-MuRF1 compared with controls with Ad-GFP transduction. B, inside-out
single BK currents were elicited from 60 mV at baseline, after exposure to
0.1 M DHS-1, and after washout (W/O). DHS-1 had no effect on mouse coro-
nary SMCs 12 h after transduction with Ad-MuRF1. Dashed lines represent the
channel closed state (c). Group data with statistical analysis are shown in the
bar graphs. N.S., not significant. C, effects of Ad-MuRF1 transduction on dose-
dependent, NS1619-mediated (10	9-10	5 M) dilation of endothelium-de-
nuded coronary arteries from non-diabetic mice. Transduction with
Ad-MuRF1 (12 h) attenuated the NS1619-induced vasodilation, but the
NS1619 response was preserved in Ad-MuRF1-treated coronaries by incuba-
tion with MG132 (10 M, 12 h). Control vessels received Ad-GFP transduction.
*, p  0.05, Ad-MuRF1 versus Ad-GFP; , p  0.05 Ad-MuRF1MG132 versus
Ad-GFP.
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these results suggest that the proteins of FLAG-BK-1(1–39) and
MuRF1BC were properly folded and that the pulldowns of
BK-1(1–39) and MuRF1BC were not due to nonspecific pro-
tein aggregation.
We also performed size exclusion chromatography separa-
tion and immunoblot analysis in Myc-MuRF1R and Myc-
MuRF1MFC mutants to determine whether the absence of
FLAG-BK-1 interaction was caused by protein misfolding be-
cause of the deletions. Myc-MuRF1R and Myc-MuRF1MFC
proteins were present in fractions 2022 (40 kDa) and 21
23 (34 kDa), respectively, similar to those we had predicted
(data not shown). Hence, a lack of protein interaction between
FLAG-BK-1 and Myc-MuRF1R or Myc-MuRF1MFC is
unlikely because of a nonspecific interaction with other
proteins.
Inhibition of Proteasomal Activity Enhanced BK-1 Expres-
sion and Restored the 1-mediated BK Channel Activation in
Diabetic Vessels—To determine whether inhibition of protea-
somal activity enhances BK channel function in diabetes, we
measured vascular BK-1 expression and BK channel activa-
tion by DHS-1 in diabetic mouse vessels. After a 24-h incuba-
tion with 10 M MG132, BK-1 expression in aortas was 2.46 

0.19-fold (n  3, p  0.05) higher than in untreated diabetic
vessels (Fig. 6A). Patch clamp studies confirmed that BK chan-
nel openings at the baseline were significantly higher in freshly
isolated coronary SMCs of diabetic mice after treatment with
MG132 (NPo  0.25 
 0.10, n  11) compared with diabetic
cells without treatment (NPo  0.018 
 0.004, n  11, p  0.05
versus MG132 treatment). Importantly, activation of BK chan-
nel by 0.1 M DHS-1 was robust in diabetic SMCs after a 12-h
treatment with MG132 (NPo  1.55 
 0.14 of MG132 treat-
ment, n  11, p  0.05 versus 0.048 
 0.016 without MG132
treatment, n  11, p  0.05), whereas DHS-1 had no significant
effects in diabetic cells without MG132 treatment (Fig. 6B).
Hence, DHS-1 increased the NPo 6.2-fold in MG132-treated
cells compared with a 2.7-fold enhancement in the cells without
MG132 treatment.
Regulation of MuRF1 Expression by NF-B in Diabetic Vessels
and in Human Coronary SMCs with HG Culture—Fig. 7A
shows that the protein expression of the NF-B1/p105,
NF-B1/p50 and p65 subunits from the aortas of diabetic mice
was increased 1.36 
 0.05-fold (n  3), 2.53 
 0.51-fold (n  3),
and 2.49 
 0.25-fold (n  3), respectively, compared with those
from controls (p  0.05 for all three). To further determine the
role of NF-B in MuRF1 and BK-1 expression, we treated NG-
and HG-cultured human coronary SMCs with 0.5 M TPCA-1
(a selective IKK2 inhibitor) (Fig. 7B). In NG-cultured cells, 24-h
TPCA-1 treatment significantly attenuated NF-B1/p105 and
NF-B1/p50 expression 0.58 
 0.06-fold and 0.81 
 0.06-fold,
respectively (n  4, p  0.05 versus controls for both), whereas
IB- expression was increased 5.66 
 0.78-fold (n  4, p 
0.05 versus controls). Moreover, TPCA-1 treatment produced a
0.86 
 0.01-fold reduction (n  4, p  0.05 versus controls) in
MuRF1 expression without a significant change in BK-1 pro-
tein level. In HG-cultured cells, IB- expression was 0.29 

0.27-fold lower than that in NG cells (n  4, p  0.05) and was
associated with a 1.54 
 0.19-fold increase in MuRF1 and a
0.61 
 0.06-fold reduction in BK-1 expression (n  4, p  0.05
versus NG in both). TPCA-1 treatment reduced NF-B1/p105
and NF-B1/p50 0.34 
 0.11-fold and 0.59 
 0.04-fold, respec-
tively (n  4, p  0.05 versus HG in both) and enhanced IB-
expression 24.8 
 0.89-fold (n  4, p  0.05 versus HG), result-
ing in a 0.56 
 0.09-fold decrease in MuRF1 expression and a
1.70 
 0.13-fold increase in BK-1 expression (n  4, p  0.05
versus HG in both). Hence, by reducing the active components
of NF-B1/50 and p65 and augmenting the expression of IB-
expression, TPCA-1 abolished NF-B/MuRF1-mediated
BK-1 degradation and protected BK-1 protein level in HG-
cultured cells.
FIGURE 4. The N terminus of BK-1 physically interacts with the coiled-coil region of MuRF1. A, schematic and protein expression of FLAG-tagged
BK-1 WT and its truncation mutants. The molecular sizes of BK-1 WT and individual mutants are shown in immunoblot analyses. Immunoprecipitates
pulled down by anti-Myc antibody were blotted against anti-FLAG antibody, showing that BK-1 WT and BK-1(1–39) proteins interacted with MuRF1
WT proteins. B, the constructs and protein expressions of Myc-MuRF1 WT and the truncation mutants. Immunoprecipitates from anti-FLAG antibodies
were blotted against anti-Myc antibody. BK-1 was only detected in Myc-MuRF1WT, Myc-MuRF1B, and Myc-MuRF1BC mutants but not in MuRF1R
and MuRF1MFC mutants. These results suggest that the coiled-coil region of MuRF1 is necessary for the interaction with the N-terminal of BK-1 but
that the RING-finger domain and the family conserved region of MuRF1 may also affect the association between MuRF1 and BK-1 proteins.
Down-regulation of Vascular BK-1 Expression by MuRF1
APRIL 11, 2014 • VOLUME 289 • NUMBER 15 JOURNAL OF BIOLOGICAL CHEMISTRY 10859
DISCUSSION
In this study, we made several novel findings. First, we found
that MuRF1 was abundantly expressed in vascular SMCs and
that the expression of MuRF1 was significantly up-regulated in
diabetic vessels and under HG culture conditions as a result of
increased NF-B signaling. Second, MuRF1 interacted physi-
cally with BK-1 and facilitated BK-1 protein ubiquitination
and degradation, leading to BK channelopathy and coronary
vasculopathy in diabetes. Third, a co-IP assay demonstrated
that the N terminus of BK-1 and the coiled-coil region of
MuRF1 were required for the formation of protein complexes.
Fourth, overexpression of MuRF1 in the coronary arteries of
non-diabetic mice mimicked the dysfunction of BK channels
and coronary arteries of diabetic mice. Most importantly,
knockdown of MuRF1 expression and pharmacological sup-
pression of proteasome and NF-B activities augmented BK-1
expression and preserved vascular BK channel function in dia-
betes and hyperglycemia. Thus, we have provided compelling
first evidence that impaired vascular BK channel function and
coronary vasodilation in diabetes is associated with an increase
of NF-B/MuRF1-dependent BK-1 degradation.
BK channel dysfunction promotes cardiovascular disorders,
including hypertension, heart failure, myocardial infarction,
stroke, retinopathy, and erectile dysfunction (45– 48). Cardio-
vascular diseases are the leading cause of death in individuals
with diabetes. The mechanisms that underlie diabetic vascular
disorders are multifactorial. Besides endothelium dysfunction,
abnormal smooth muscle function also critically contributes to
vascular pathology in diabetes, especially under the long-term
conditions of glucotoxicity and lipotoxicity (49). A major cause
of diabetic BK channel abnormality is attributed to the down-
regulation of BK-1 expression in vascular SMCs (26, 27),
resulting in impaired BK channel sensitivity to Ca2 and volt-
age activation (26, 27). Many signaling pathways have been
reported to be involved in the regulation of BK-1 protein
expression. For instance, it has been shown that the activation
of calcineurin/nuclear factor of activated T-cells, cytoplasmic 3
(NFATC3) signaling suppressed vascular BK-1 expression in
angiotensin II-induced hypertensive mice (50). We have also
reported previously that the down-regulation of BK-1 expres-
sion in diabetes and under HG culture conditions is ubiquitin/
proteasome-dependent (28). In our previous study, we have
FIGURE 5. Size exclusion chromatography separation of the FLAG-BK-
1(1–39) and Myc-MuRF1BC mutations. A, after 48 h of transfection of a
vector containing FLAG-BK-1(1–39) or Myc-MuRF1BC mutants in HEK293
cells, cells were homogenized. 350 l of cell lysates was loaded onto a size
exclusion column (Sephadex 75 10/300 column, 10  30 cm, bed volume 
23.5 ml) at a flow rate of 0.4 ml/min. Forty-eight fractions of 0.4 ml each were
collected. Immunoblot analyses show that FLAG-BK-1(1–36) was detected
in fractions 2326 with an estimated size of 17 kDa (top panel) and that Myc-
MuRF1BC was present in fractions 2325 with an estimated molecule
weight about 27 kDa. B, the distributions of FLAG-BK-1(1–39) (black line) and
Myc-MuRF1BC (red line) protein expression with protein markers (green
line). Five protein standards with different molecular weights were separated
under the same running conditions: 1, bovine thyroglobulin, 670 kDa; 2,
bovine IgG, 158 kDa; 3, chicken ovalbumin, 44 kDa; 4, horse myoglobin, 17
kDa; and 5, vitamin B12, 1.35 kDa. AU: UV absorbance at 280 nm.
FIGURE 6. Enhanced BK-1 expression and BK-1-mediated channel acti-
vation by MG132. A, protein expression of BK-1 in STZ-induced diabetic
aortas with or without 24-h treatment of MG132 (10 M). Inhibition of protea-
somal activity by MG132 increased BK-1 protein expression in diabetic ves-
sels. B, robust BK channel openings by DHS-1 (0.1 M) were observed in
freshly isolated diabetic coronary SMCs after 12-h incubation with MG132.
Group data with statistical analysis are shown in the bar graphs. Dashed lines
represent the channel closed state (c). W/O, washout.
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found that atrogin-1, another E3, regulated BK-1 expression
through interaction with the PDZ-binding motif in BK-1 that
facilitated BK-1 protein ubiquitination (28). Moreover, the
expression of atrogin-1 in diabetic vessels was up-regulated by
oxidative stress-mediated up-regulation of forkhead box O
transcription factor-3a (Foxo3a)-dependent atrogin-1 mRNA
transcription (31). Foxo3a activity is dependent on its subcellu-
lar localization. Inhibition of Akt signaling by oxidative stress
leads to Foxo3a nuclear translocation and facilitates Foxo bio-
logical function (51, 52). In this study, we further demonstrated
that MuRF1 expression was similarly increased in diabetic ves-
sels and also contributed significantly to BK-1 dysfunction.
Interestingly, MuRF1 mRNA and protein are only expressed in
vascular SMCs, whereas those of atrogin-1 can be detected in
both vascular SMCs and the vascular endothelium (data not
shown). The PDZ motif of BK-1 is located at the extracellular
loop, whereas the N terminus of BK-1 is intracellular. Hence,
interaction between atrogin-1 and BK-1 must occur before
BK-1 transportation to the sarcolemmal membrane. It is
worth emphasizing that UPS is presented in the centrosomes
and cytoskeletal networks as well as the outer surface of the
endoplasmic reticulum and that UPS-associated proteolysis
can take place at different cell organelles, dependent on the
location of E3 recognizing motifs of substrates (53, 54). An
increase of both MuRF1 and atrogin-1 expression in diabetic
vessels may synergistically accelerate BK-1 protein degrada-
tion at different stages of protein metabolism and exacerbate
BK channel-mediated vascular dysfunction in diabetes.
MuRF1 transcription is controlled by NF-B (55). It is known
that NF-B activation is a key event for the initiation of cardio-
vascular pathogenesis in diabetes as a result of increased oxida-
tive stress (56, 57). We found that the protein levels of the
NF-B1/p50 and p65 subunits were augmented in diabetic ves-
sels and in HG-cultured human coronary SMCs. Pretreatment
with the IKK-2 inhibitor TPCA-1 significantly increased IB
expression and reduced NF-B/p50 expression in both NG-
and HG-cultured human coronary SMCs, but the effects of
TPCA-1 were more potent under HG culture conditions, which
maintained BK-1 expression in HG-cultured cells to the level
of NG-cells. Hence, NF-B/MuRF1/BK-1 should be consid-
ered a potential therapeutic target for diabetic coronary dys-
function (Fig. 8).
The specificity of substrate degradation by the proteasome is
dependent on the E3 ligase. It has been confirmed that the E3
ligase Nedd-4 interacts with the PY motifs in the C terminus of
the cardiac voltage-gated Na channel (Nav1.5), the epithelial
Na channel, and the voltage gated K channel and leads to
channel ubiquitination and degradation (58 – 60). We found
that Nedd-4 did not regulate BK-1 expression even though
there is a PY motif at the extracellular loop of BK- (data not
shown), suggesting that the three-dimensional protein folding
is critical. Many regions of MuRF1 have been reported to be
associated with substrate proteins. For instance, MuRF1 inter-
acts with the hydrophobic amino acids of “Titin repeats” (61)
and myosin heavy chain in skeletal muscles (62). The coiled-coil
FIGURE 7. Regulation of MuRF1 and BK-1 expression by NF-B. A, protein
expression of NF-B1/p105, NF-B1/p50, and RelA/p-65 in the aortas of con-
trol and STZ-induced diabetic mice. The levels of NF-B/p105, NF-B1/p50,
and p-65 protein expression were significantly increased in diabetic mice
compared with controls (Ctrl). B, 24-h incubation with 0.5 M TPCA-1 sup-
pressed the levels of NF-B1/p105, NF-B1/p50, and MuRF1 expression but
markedly increased that of IB- in both NG- and HG-cultured human coro-
nary SMCs. TPCA-1 treatment did not alter BK-1 expression in NG-cultured
cells but significantly enhanced that in HG-cultured cells. Group data and
statistical analysis are shown in the bar graphs.
FIGURE 8. A proposed model for NF-B/MuRF1-dependent BK-1 protein
degradation in diabetic vessels. In diabetic vessels, increased NF-B/p50
and p65 expression stimulates MuRF1 mRNA transcription and protein
expression. The coiled-coil domain of MuRF1 interacts with the N terminus of
BK-1, which induces BK-1 protein ubiquitination and degradation through
the UPS and leads to diminished BK channel activation and coronary vasodi-
lation. TPCA-1 inhibits IKK-2 activity, which decreases IB phosphorylation
and prevents its dissociation from NF-B/p65, thereby down-regulating
MuRF1 expression. MG132 inhibits proteasomal activity and reduces BK-1
proteolysis.
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region of MuRF1 is responsible for the binding of troponin I in
cardiomyocytes (63). The MuRF family conserved region is
required for the interaction with phospho-c-Jun in the heart
(64). Using BK-1 and MuRF1 truncation mutants and a co-IP
assay, we have identified the functional domains for physical
interaction between BK-1 and MuRF1. The N terminus of
BK-1 is the only region that interacts with MuRF1. The coun-
terparts in MuRF1 are more complicated. We believe that the
coiled-coil region of MuRF1 is the structure required for
recruiting BK-1 to MuRF1 because BK-1 can be detected in
the pulldown of the MuRF1 coiled-coil region alone, but a
direct protein binding experiment is required to further con-
firm our findings. Our results are similar to previous observa-
tions that the coiled-coil region is sufficient for MuRF1 binding
to sarcomeric M-line titin and thick filament (63). Interestingly,
partially deleting the RING finger domain or the family con-
served region of MuRF1 interferes with the physical association
with BK-1. One explanation is that the RING finger domain
and the MuRF1 family conserved region are also important for
proper three-dimensional protein folding that allows the
coiled-coil region to bind with the N terminus of BK-1. How
the RING finger domain and the family conserved region influ-
ence the interaction between MuRF1 and BK-1 is currently
unclear and needs further investigation using in vitro protein
binding assays. Nevertheless, this is the first report that MuRF1
physically interacts with BK-1, facilitates BK-1 protein deg-
radation, and impairs BK channel function in diabetic vessels.
Inhibition of MuRF1 expression protects BK-1 expression and
vascular BK channel function and preserves coronary vasoreac-
tivity in diabetes.
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